TNFSF13B and systemic lupus erythematosus: Hence, BAFF-targeting therapy, by using therapeutic agents that block BAFF activity, is a promising area currently undergoing clinical trials, for the treatment of B-cell-related autoimmune diseases, particularly SLE.